WEKO3
アイテム
Cost-effectiveness analysis of palbociclib as first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer in Japan
https://iuhw.repo.nii.ac.jp/records/1104
https://iuhw.repo.nii.ac.jp/records/11044690d72c-4361-4678-a850-2a24d6083eef
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
本文(PDF) (524.7 kB)
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2021-03-02 | |||||||||||
| タイトル | ||||||||||||
| タイトル | Cost-effectiveness analysis of palbociclib as first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer in Japan | |||||||||||
| 言語 | en | |||||||||||
| 言語 | ||||||||||||
| 言語 | eng | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
| 資源タイプ | journal article | |||||||||||
| キーワード | ||||||||||||
| 言語 | ja | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | パルボシクリブ | |||||||||||
| キーワード | ||||||||||||
| 言語 | ja | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | レトロゾール | |||||||||||
| キーワード | ||||||||||||
| 言語 | ja | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | 費用効用分析 | |||||||||||
| キーワード | ||||||||||||
| 言語 | ja | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | 手術不能又は再発乳がん | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | palbociclib | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | letrozole | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | Cost-effectiveness | |||||||||||
| キーワード | ||||||||||||
| 言語 | en | |||||||||||
| 主題Scheme | Other | |||||||||||
| 主題 | advanced breast cancer | |||||||||||
| 著者 |
MORIMOTO, Takashi
× MORIMOTO, Takashi
× IKEDA, SHUNYA
× YAMAZAKI, Tsutomu
|
|||||||||||
| 著者別名 | ||||||||||||
| 姓名 | MORIMOTO, Takashi | |||||||||||
| 著者別名 | ||||||||||||
| 姓名 | IKEDA, SHUNYA | |||||||||||
| 著者別名 | ||||||||||||
| 姓名 | YAMAZAKI, Tsutomu | |||||||||||
| 内容記述 | ||||||||||||
| 内容記述タイプ | Other | |||||||||||
| 内容記述 | Purpose: To evaluate the cost-effectiveness of palbociclib (PAL) plus letrozole (LET) compared with LET alone as first-line therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) unresectable or recurrent breast cancer. Methods: We developed a Markov model to estimate the cost-effectiveness of PAL plus LET compared with LET alone over a 15-year period. Cost-effectiveness analysis was performed from the Japanese healthcare payerʼ s perspective. Clinical outcomes were derived from the PALOMA-1 and PALOMA-2 studies. Quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Direct medical costs and QALY were discounted at 2% per year. One-way sensitivity analyses were performed to estimate the uncertainty of the results. Results: Incremental costs and QALY when PAL was added to LET therapy were 8,670,801 JPY and 0.388 QALY, respectively. ICER between PAL plus LET and LET alone was 22,345,821 JPY/QALY. ICER exceeded 7.5 million JPY/ QALY, which was the willingness-to-pay threshold for anti-cancer drugs in Japan. According to one-way sensitivity analyses, PAL plus LET therapy was not cost-effective. Conclusion: PAL plus LET was not cost-effective compared with LET alone for first-line treatment of advanced breast cancer in Japan. |
|||||||||||
| 言語 | en | |||||||||||
| 書誌情報 |
ja : 国際医療福祉大学学会誌 en : Journal of the International University of Health and Welfare 巻 26, 号 1, p. 17-25, 発行日 2021-02-20 |
|||||||||||
| 出版者 | ||||||||||||
| 出版者 | 国際医療福祉大学学会 | |||||||||||
| 言語 | ja | |||||||||||
| ISSN | ||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||
| 収録物識別子 | 21863652 | |||||||||||
| 書誌レコードID（NCID） | ||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||
| 収録物識別子 | AA12537130 | |||||||||||
| 著者版フラグ | ||||||||||||
| 言語 | en | |||||||||||
| 値 | publisher | |||||||||||
